Drug intelligence / Profile preview

MAK5206

Development stage: Preclinical
Lead developer: MAK Scientific
Modality: Small Molecules

Overview

**MAK5206** is a potent fatty acid amide hydrolase (FAAH) inhibitor developed by MAKScientific with demonstrated neuroprotective properties and an excellent safety profile. FAAH inhibitors elevate endocannabinoid levels, providing therapeutic potential in neurodegenerative diseases by modulating neuroinflammation and neuronal protection. It was specifically explored as a candidate medication for **multiple sclerosis (MS)**, with Biogen Idec (now Biogen) securing an option on MAKScientific's MS program encompassing this compound.

Targets

FAAH

Beyond the preview

Go deeper on MAK5206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAK5206.

Explore the full profile